TAKKT (TTK) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
28 Oct, 2026Executive summary
9M organic sales declined 5.1%; Q3 organic sales fell 4.3%, virtually unchanged from Q2, while gross margin remained slightly above prior year.
A cyberattack discovered Oct. 19 was contained, but recovery restrictions continue to constrain order processing, deliveries and invoicing.
Cyber disruption creates significant downside risk to Q4 sales, earnings and cash flow; recovery pace and delayed-order conversion are pivotal.
Financial highlights
Q3 sales were €231.8m, down 5.2% reported and 4.3% organically; 9M sales were €685.6m, down 6.9% reported and 5.1% organically.
Q3 EBITDA was €5.6m versus €10.5m; 9M EBITDA was €14.5m versus €27.3m. Adjusted EBITDA margins were 3.0% and 3.2%, respectively, versus 4.3% in each prior-year period.
9M gross margin was 39.2% versus 39.0%; cost-base savings partly offset lower sales, while one-time expenses totaled €7.3m.
9M EBIT was -€23.7m versus €4.4m; net income was -€28.3m versus -€0.2m, and EPS was -€0.44 versus €0.00.
Outlook and guidance
FY 2026 guidance remains organic sales growth of -7% to +3% and adjusted EBITDA margin of 2% to 5%; cyber disruption raises the risk of results at the low end or below.
The attack is expected to weigh noticeably on Q4 sales, earnings and cash flow; its total financial impact is not yet reliably quantifiable.
Negative FY free cash flow risk has increased; recovery speed and net working capital reduction are key to Q4 cash generation.
Management expects gradual rather than sharp market improvement in 2027.
Latest events from TAKKT
- Higher gross margin and cash flow cushioned weaker sales; €1.00 dividend proposed.TTK
Q4 2023 - H1 2026 saw sales down 7.7%, a 3.3% EBITDA margin, and guidance confirmed.TTK
Q2 2026 - Operational efficiency and digital growth drive recovery amid market volatility and declining sales.TTK
Investor presentation - Sales fell 10.3% with margin pressure, but guidance and strategic focus remain unchanged.TTK
Q1 2026 - 2025 sales fell 6.6% with lower earnings, but structural gains set up margin recovery in 2026.TTK
Q4 2025 - Sales and EBITDA fell in 2025, but free cash flow stayed positive and dividend was suspended.TTK
Q4 2025 TU - Sales and profit remain under pressure, but operational fixes are driving gradual improvement.TTK
Q3 2024 - Sales and profit fell sharply in H1 2024, but cash flow and margins showed resilience.TTK
Q2 2024 - Sales fell 15.4% in 2024, but strong cash flow and a EUR 0.60 dividend proposal support recovery.TTK
Q4 2024